NCT02762981View on ClinicalTrials.gov

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 23, 2016

Primary Completion Date

May 12, 2020

Study Completion Date

September 12, 2020

Conditions
Solid Tumors
Interventions
DRUG

Relacorilant with nab-paclitaxel

Relacorilant is supplied as capsules for oral dosing. Nab-paclitaxel administered as an IV infusion.

Trial Locations (4)

60637

001, Chicago

84403

013, Ogden

85258

038, Scottsdale

94143

014, San Francisco

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY

NCT02762981 - Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter